



March 14, 2023

XXXXX  
XXXXX  
XXXXX

Re: Request for Action on Medical Research Matter; Nonhuman Primate Model Crisis

Dear xxxx:

We, the undersigned companies, organizations and institutions are actively engaged in conducting and supporting essential medical research on virtually all diseases affecting the American population. Our companies and institutions represent the majority of drug and biomedical research and development work conducted in the United States, which is critical not only to preventing the spread of infectious diseases like COVID-19, but also for the development of new innovative treatments for cancer, diabetes, and a number of other diseases currently without effective treatment options.

We are currently experiencing a crisis in which 60% of the supply of non-human primates (NHPs) critical to this work are being denied permits by the U.S. Fish and Wildlife Service. This disruption will significantly slow the U.S. biopharmaceutical pipeline, stifle scientific advancement, impair research, halt industry-wide economic growth, and deprive patients of potentially life-saving treatments. The gravity of this situation cannot be understated. A sustainable solution to this critical issue is urgently needed for all stakeholders.

Non-human primates (NHP's) have been in high demand in recent years, due in part to the focus on biologic drug pipelines as well as the need to use these models in regulatory-required drug safety testing. Because of their close genetic, physiological, and behavioral similarity to humans, NHPs are often the only relevant animal models for critical translational research.

We understand the issue at hand is the alleged illegal inclusion of wild-caught animals with captive bred animals from Cambodia and agree with the long-term goal of suppliers needing to provide accurate descriptions of all legally imported animals. We are asking that our government work with us in finding both short-term and long-term solutions to this crisis such that the pipeline for lifesaving medications will continue without interruption

We are committed to convening conversations and sharing our knowledge, expertise, and insights with any and all public and private sector stakeholders in order to develop and facilitate the implementation of solutions. We look forward to partnering with the U.S. government to quickly secure the U.S. supply chain and find long-term solutions for nonhuman primate resource needs.

Sincerely,

**Altasciences**

**American College of Neuropsychopharmacology**

**American Physiological Society (APS)**

**American Veterinary Medical Association (AVMA)**

**Americans for Medical Progress**

**Association for Research in Vision and Ophthalmology (ARVO)**

**Attralus**

**BioImpact Capital**

**Biotechnology Innovation Organization (BIO)**

**California Biomedical Research Association (CBRA)**

**Charles River Laboratories**

**Context Therapeutics**

**Emory National Primate Research Center**

**Federation of American Societies for Experimental Biology (FASEB)**

**Inotiv**

**Labcorp**

**Massachusetts Society for Medical Research (MSMR)**

**Missouri Biotechnology Association (MOBIO)**

**MPM Capital**

**Northern Biomedical Research**

**Oregon National Primate Research Center**

**Orna Therapeutics**

**ReNAgade Therapeutics**



National Association *for*  
Biomedical Research

**Texas Biomedical Research Institute**

**Texas Society for Biomedical Research (TSBR)**

**Tulane National Primate Research Center**

**Virscio, Inc.**

**Washington National Primate Research Center**